Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Wages, Salaries and Other
Others
Ratios

CNBX Pharmaceuticals (CNBX) EBT (2016 - 2025)

CNBX Pharmaceuticals (CNBX) has disclosed EBT for 13 consecutive years, with -$64002.0 as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, EBT fell 73.74% year-over-year to -$64002.0, compared with a TTM value of -$298856.0 through Nov 2025, up 33.3%, and an annual FY2025 reading of -$313976.0, up 48.21% over the prior year.
  • EBT was -$64002.0 for Q4 2025 at CNBX Pharmaceuticals, up from -$129731.0 in the prior quarter.
  • Across five years, EBT topped out at -$36837.0 in Q4 2024 and bottomed at -$1.3 million in Q2 2021.
  • Average EBT over 5 years is -$376888.8, with a median of -$189755.0 recorded in 2023.
  • The sharpest move saw EBT skyrocketed 78.57% in 2024, then crashed 146.95% in 2025.
  • Year by year, EBT stood at -$1.1 million in 2021, then soared by 68.77% to -$346790.0 in 2022, then skyrocketed by 50.43% to -$171900.0 in 2023, then surged by 78.57% to -$36837.0 in 2024, then tumbled by 73.74% to -$64002.0 in 2025.
  • Business Quant data shows EBT for CNBX at -$64002.0 in Q4 2025, -$129731.0 in Q3 2025, and -$40380.0 in Q2 2025.